<p>Ralliant（纽约证券交易所代码：RAL - 获取免费报告）在周一发布给投资者的报告中，巴克莱分析师将其目标价从 60.00 美元下调至 52.00 美元，Benzinga 报道。该公司目前对该股票的评级为 “增持”。巴克莱的目标价意味着该股票当前价格有 31.65% 的潜在上涨空间。</p>
<p>RAL 已经成为其他多份报告的主题。Oppenheimer 在周五的研究报告中将 Ralliant 的目标价从 60.00 美元下调至 50.00 美元，并对该股票给予 “跑赢大盘” 的评级。摩根士丹利在周五重申了 “增持” 评级，并对 Ralliant 的股票设定了 45.00 美元的目标价。Truist Financial 在周五将 Ralliant 的目标价从 62.00 美元下调至 49.00 美元，并对该公司设定了 “买入” 评级。加拿大皇家银行在周五的研究报告中将 Ralliant 的目标价从 52.00 美元下调至 41.00 美元，并对该股票设定了 “行业表现” 的评级。最后，Weiss Ratings 在周四的研究报告中将 Ralliant 的股票评级从 “持有（c）” 下调至 “卖出（d）”。七位研究分析师对该股票给予了买入评级，三位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，平均目标价为 50.50 美元。</p>
<p><strong>阅读我们最新的 Ralliant 股票分析</strong></p>
<h2>Ralliant 股价上涨 2.9%</h2>
<p>周一，NYSE RAL 的股票开盘价为 39.50 美元。Ralliant 的 52 周低点为 37.27 美元，52 周高点为 57.02 美元。该股票的 50 日移动平均价格为 51.52 美元，200 日移动平均价格为 46.72 美元。该股票的市值为 44.6 亿美元，市盈率为 31.10。该公司的速动比率为 0.58，流动比率为 0.84，债务与股本比率为 0.38。</p>
<p>Ralliant（NYSE:RAL - 获取免费报告）最近于 2 月 4 日（星期三）发布了季度财报。该公司报告每股收益（EPS）为 0.69 美元，超出分析师一致预期的 0.67 美元，超出幅度为 0.02 美元。该公司季度收入为 5.546 亿美元，而分析师预期为 5.4304 亿美元。与去年同期相比，该公司的季度收入增长了 1.2%。Ralliant 对 2026 年第一季度的指引为每股收益 0.460-0.520 美元，对 2026 财年的指引为每股收益 2.220-2.420 美元。</p>
<h2>内部活动</h2>
<p>在其他 Ralliant 新闻中，高级副总裁 Amir A. Kazmi 于 2 月 6 日（星期五）购买了 2,545 股该公司的股票。每股平均购买价格为 39.27 美元，总交易额为 99,942.15 美元。收购后，该高级副总裁直接持有 39,699 股公司股票，价值约为 1,558,979.73 美元。这笔交易代表其持股增加了 6.85%。该收购在向 SEC 提交的文件中披露，相关文件可通过此链接访问。此外，董事 Kevin E. Bryant 于 2 月 6 日（星期五）购买了 1,250 股该股票。每股平均购买成本为 39.97 美元，总价值为 49,962.50 美元。完成购买后，该董事在公司持有 4,653 股，价值 185,980.41 美元。这代表其持股增加了 36.73%。该购买的 SEC 文件提供了更多信息。</p>
<h2>机构投资者对 Ralliant 的看法</h2>
<p>对冲基金和其他机构投资者最近增加或减少了对该公司的持股。Dodge &amp; Cox 在第二季度购买了价值约 523,571,000 美元的 Ralliant 新股份。Viking Global Investors LP 在第二季度收购了价值约 257,200,000 美元的 Ralliant 新股份。State Street Corp 在第二季度购买了价值约 213,096,000 美元的 Ralliant 新股份。Flossbach Von Storch SE 在第二季度收购了价值约 198,077,000 美元的 Ralliant 新股份。最后，挪威银行在第二季度购买了价值约 108,453,000 美元的 Ralliant 新股份。</p>
<h2>Ralliant 公司简介</h2>
<p>（获取免费报告）</p>
<p>Ralliant, Inc（NYSE: RAL）是一家医疗技术公司，专注于在再生医学领域提供即时细胞治疗解决方案。该公司开发和销售系统，能够直接从患者自身的脂肪组织中分离、浓缩和储存脂肪来源的间充质血管成分（SVF）细胞，从而实现无需广泛实验室基础设施的同日自体治疗。</p>
<p>该公司的核心产品组合包括专有设备平台和一次性处理套件，旨在简化临床医生的工作流程。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票比 Ralliant 更好</li>
<li>你的银行账户不再安全</li>
<li>黄金市场崩溃的那一天</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>他刚刚准确预测了另一个黄金走势……</li>
<li>~$1.5T SpaceX IPO：首次公开募股机会</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVJBTA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVJBTA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Ralliant 吗？</h2>
<p>在你考虑 Ralliant 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 Ralliant 并不在名单上。</p>
<p>虽然 Ralliant 目前在分析师中被评为适度买入，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

<p>巴克莱将 Ralliant（纽约证券交易所代码：RAL）的目标价从 60.00 美元下调至 52.00 美元，同时维持 “增持” 评级。这个新目标暗示从当前价格来看有 31.65% 的潜在上涨空间。其他分析师也调整了他们的目标价，Oppenheimer 将其设定为 50.00 美元，摩根士丹利则为 45.00 美元。Ralliant 的股票开盘价为 39.50 美元，市值为 44.6 亿美元。近期的内部人士购买表明对公司未来的信心。Ralliant 专注于再生医学的医疗技术，重点提供即时细胞治疗解决方案</p>

<p>Ralliant (NYSE:RAL - Get Free Report) had its target price decreased by analysts at Barclays from $60.00 to $52.00 in a note issued to investors on Monday,Benzinga reports. The firm currently has an &#34;overweight&#34; rating on the stock. Barclays's price objective would indicate a potential upside of 31.65% from the stock's current price.</p>
<div class="lb-trans"><p>Ralliant（纽约证券交易所代码：RAL - 获取免费报告）在周一发布给投资者的报告中，巴克莱分析师将其目标价从 60.00 美元下调至 52.00 美元，Benzinga 报道。该公司目前对该股票的评级为 “增持”。巴克莱的目标价意味着该股票当前价格有 31.65% 的潜在上涨空间。</p>
</div><p>RAL has been the topic of a number of other reports. Oppenheimer dropped their price target on shares of Ralliant from $60.00 to $50.00 and set an &#34;outperform&#34; rating on the stock in a research note on Friday. Morgan Stanley restated an &#34;overweight&#34; rating and issued a $45.00 price objective on shares of Ralliant in a research note on Friday. Truist Financial dropped their price objective on shares of Ralliant from $62.00 to $49.00 and set a &#34;buy&#34; rating for the company in a research note on Friday. Royal Bank Of Canada reduced their price target on shares of Ralliant from $52.00 to $41.00 and set a &#34;sector perform&#34; rating on the stock in a research report on Friday. Finally, Weiss Ratings cut shares of Ralliant from a &#34;hold (c)&#34; rating to a &#34;sell (d)&#34; rating in a research report on Thursday. Seven research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of &#34;Moderate Buy&#34; and an average target price of $50.50.</p>
<div class="lb-trans"><p>RAL 已经成为其他多份报告的主题。Oppenheimer 在周五的研究报告中将 Ralliant 的目标价从 60.00 美元下调至 50.00 美元，并对该股票给予 “跑赢大盘” 的评级。摩根士丹利在周五重申了 “增持” 评级，并对 Ralliant 的股票设定了 45.00 美元的目标价。Truist Financial 在周五将 Ralliant 的目标价从 62.00 美元下调至 49.00 美元，并对该公司设定了 “买入” 评级。加拿大皇家银行在周五的研究报告中将 Ralliant 的目标价从 52.00 美元下调至 41.00 美元，并对该股票设定了 “行业表现” 的评级。最后，Weiss Ratings 在周四的研究报告中将 Ralliant 的股票评级从 “持有（c）” 下调至 “卖出（d）”。七位研究分析师对该股票给予了买入评级，三位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，平均目标价为 50.50 美元。</p>
</div><p><strong>Read Our Latest Stock Analysis on Ralliant</strong></p>
<div class="lb-trans"><p><strong>阅读我们最新的 Ralliant 股票分析</strong></p>
</div><h2>Ralliant Trading Up 2.9%</h2>
<div class="lb-trans"><h2>Ralliant 股价上涨 2.9%</h2>
</div><p>Shares of NYSE RAL opened at $39.50 on Monday. Ralliant has a 52-week low of $37.27 and a 52-week high of $57.02. The stock's 50 day moving average price is $51.52 and its two-hundred day moving average price is $46.72. The stock has a market capitalization of $4.46 billion and a P/E ratio of 31.10. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.38.</p>
<div class="lb-trans"><p>周一，NYSE RAL 的股票开盘价为 39.50 美元。Ralliant 的 52 周低点为 37.27 美元，52 周高点为 57.02 美元。该股票的 50 日移动平均价格为 51.52 美元，200 日移动平均价格为 46.72 美元。该股票的市值为 44.6 亿美元，市盈率为 31.10。该公司的速动比率为 0.58，流动比率为 0.84，债务与股本比率为 0.38。</p>
</div><p>Ralliant (NYSE:RAL - Get Free Report) last released its quarterly earnings results on Wednesday, February 4th. The company reported $0.69 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.67 by $0.02. The firm had revenue of $554.60 million for the quarter, compared to analyst estimates of $543.04 million. The business's quarterly revenue was up 1.2% compared to the same quarter last year. Ralliant has set its Q1 2026 guidance at 0.460-0.520 EPS and its FY 2026 guidance at 2.220-2.420 EPS.</p>
<div class="lb-trans"><p>Ralliant（NYSE:RAL - 获取免费报告）最近于 2 月 4 日（星期三）发布了季度财报。该公司报告每股收益（EPS）为 0.69 美元，超出分析师一致预期的 0.67 美元，超出幅度为 0.02 美元。该公司季度收入为 5.546 亿美元，而分析师预期为 5.4304 亿美元。与去年同期相比，该公司的季度收入增长了 1.2%。Ralliant 对 2026 年第一季度的指引为每股收益 0.460-0.520 美元，对 2026 财年的指引为每股收益 2.220-2.420 美元。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部活动</h2>
</div><p>In other Ralliant news, SVP Amir A. Kazmi acquired 2,545 shares of the business's stock in a transaction dated Friday, February 6th. The shares were acquired at an average price of $39.27 per share, for a total transaction of $99,942.15. Following the acquisition, the senior vice president directly owned 39,699 shares of the company's stock, valued at approximately $1,558,979.73. This trade represents a 6.85% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Kevin E. Bryant bought 1,250 shares of the stock in a transaction that occurred on Friday, February 6th. The shares were acquired at an average cost of $39.97 per share, with a total value of $49,962.50. Following the completion of the purchase, the director owned 4,653 shares in the company, valued at $185,980.41. This represents a 36.73% increase in their position. The SEC filing for this purchase provides additional information.</p>
<div class="lb-trans"><p>在其他 Ralliant 新闻中，高级副总裁 Amir A. Kazmi 于 2 月 6 日（星期五）购买了 2,545 股该公司的股票。每股平均购买价格为 39.27 美元，总交易额为 99,942.15 美元。收购后，该高级副总裁直接持有 39,699 股公司股票，价值约为 1,558,979.73 美元。这笔交易代表其持股增加了 6.85%。该收购在向 SEC 提交的文件中披露，相关文件可通过此链接访问。此外，董事 Kevin E. Bryant 于 2 月 6 日（星期五）购买了 1,250 股该股票。每股平均购买成本为 39.97 美元，总价值为 49,962.50 美元。完成购买后，该董事在公司持有 4,653 股，价值 185,980.41 美元。这代表其持股增加了 36.73%。该购买的 SEC 文件提供了更多信息。</p>
</div><h2>Institutional Investors Weigh In On Ralliant</h2>
<div class="lb-trans"><h2>机构投资者对 Ralliant 的看法</h2>
</div><p>Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Dodge &amp; Cox bought a new position in shares of Ralliant in the 2nd quarter valued at about $523,571,000. Viking Global Investors LP acquired a new position in Ralliant during the second quarter valued at approximately $257,200,000. State Street Corp bought a new position in Ralliant in the second quarter valued at approximately $213,096,000. Flossbach Von Storch SE acquired a new position in shares of Ralliant during the 2nd quarter worth approximately $198,077,000. Finally, Norges Bank bought a new stake in shares of Ralliant during the 2nd quarter worth approximately $108,453,000.</p>
<div class="lb-trans"><p>对冲基金和其他机构投资者最近增加或减少了对该公司的持股。Dodge &amp; Cox 在第二季度购买了价值约 523,571,000 美元的 Ralliant 新股份。Viking Global Investors LP 在第二季度收购了价值约 257,200,000 美元的 Ralliant 新股份。State Street Corp 在第二季度购买了价值约 213,096,000 美元的 Ralliant 新股份。Flossbach Von Storch SE 在第二季度收购了价值约 198,077,000 美元的 Ralliant 新股份。最后，挪威银行在第二季度购买了价值约 108,453,000 美元的 Ralliant 新股份。</p>
</div><h2>Ralliant Company Profile</h2>
<div class="lb-trans"><h2>Ralliant 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Ralliant, Inc NYSE: RAL is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient's own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.</p>
<div class="lb-trans"><p>Ralliant, Inc（NYSE: RAL）是一家医疗技术公司，专注于在再生医学领域提供即时细胞治疗解决方案。该公司开发和销售系统，能够直接从患者自身的脂肪组织中分离、浓缩和储存脂肪来源的间充质血管成分（SVF）细胞，从而实现无需广泛实验室基础设施的同日自体治疗。</p>
</div><p>The company's core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.</p>
<div class="lb-trans"><p>该公司的核心产品组合包括专有设备平台和一次性处理套件，旨在简化临床医生的工作流程。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Ralliant</li>
<li>Your Bank Account Is No Longer Safe</li>
<li>The day the gold market broke</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
<li>He just nailed another gold prediction …</li>
<li>~$1.5T SpaceX IPO: Pre-IPO Opportunity</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Ralliant 更好</li>
<li>你的银行账户不再安全</li>
<li>黄金市场崩溃的那一天</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>他刚刚准确预测了另一个黄金走势……</li>
<li>~$1.5T SpaceX IPO：首次公开募股机会</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVJBTA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NYSE&amp;Symbol=RAL"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Ralliant Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Ralliant 吗？</h2>
</div><p>Before you consider Ralliant, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Ralliant 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ralliant wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 Ralliant 并不在名单上。</p>
</div><p>While Ralliant currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Ralliant 目前在分析师中被评为适度买入，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

巴克莱银行将 Ralliant（纽约证券交易所代码：RAL）的目标股价下调至 52.00 美元